Literature DB >> 34484924

Medication Costs Harm Patients With Multiple Sclerosis.

Marc R Nuwer1, Kevin Patel1.   

Abstract

Entities:  

Year:  2021        PMID： 34484924      PMCID： PMC8382395          DOI： 10.1212/CPJ.0000000000000927

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN： 2163-0402


× No keyword cloud information.
  6 in total

1.  Cost sharing, benefit design, and adherence: the case of multiple sclerosis.

Authors:  Avi Dor; Maureen J Lage; Marcy L Tarrants; Jane Castelli-Haley
Journal:  Adv Health Econ Health Serv Res       Date:  2010

2.  Impact of Cost-Sharing Increases on Continuity of Specialty Drug Use: A Quasi-Experimental Study.

Authors:  Pengxiang Li; Tianyan Hu; Xinyan Yu; Salim Chahin; Nabila Dahodwala; Marissa Blum; Amy R Pettit; Jalpa A Doshi
Journal:  Health Serv Res       Date:  2017-07-24       Impact factor: 3.402

3.  Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.

Authors:  Katharine Harding; Owain Williams; Mark Willis; James Hrastelj; Anthony Rimmer; Fady Joseph; Valentina Tomassini; Mark Wardle; Trevor Pickersgill; Neil Robertson; Emma Tallantyre
Journal:  JAMA Neurol       Date:  2019-05-01       Impact factor: 18.302

4.  Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.

Authors:  Anna He; Bernd Merkel; James William L Brown; Lana Zhovits Ryerson; Ilya Kister; Charles B Malpas; Sifat Sharmin; Dana Horakova; Eva Kubala Havrdova; Tim Spelman; Guillermo Izquierdo; Sara Eichau; Maria Trojano; Alessandra Lugaresi; Raymond Hupperts; Patrizia Sola; Diana Ferraro; Jan Lycke; Francois Grand'Maison; Alexandre Prat; Marc Girard; Pierre Duquette; Catherine Larochelle; Anders Svenningsson; Thor Petersen; Pierre Grammond; Franco Granella; Vincent Van Pesch; Roberto Bergamaschi; Christopher McGuigan; Alasdair Coles; Jan Hillert; Fredrik Piehl; Helmut Butzkueven; Tomas Kalincik
Journal:  Lancet Neurol       Date:  2020-03-18       Impact factor: 44.182

5.  Cost Sharing of Disease-Modifying Treatments (DMTs) as Policy Lever to Improve DMTs' Access in Multiple Sclerosis.

Authors:  Hui Shao; Charles Stoecker; Alisha M Monnette; Lizheng Shi
Journal:  Value Health       Date:  2018-01-08       Impact factor: 5.725

6.  Cost-sharing and initiation of disease-modifying therapy for multiple sclerosis.

Authors:  John Romley; Dana Goldman; Michael Eber; Homa Dastani; Edward Kim; Swetha Raparla
Journal:  Am J Manag Care       Date:  2012-08       Impact factor: 2.229
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.